Keith Michael Sullivan, MD

Professor of Medicine
James B. Wyngaarden Professor of Medicine, in the School of Medicine
Member of the Duke Cancer Institute
Campus mail Box 3961 Med Ctr, Durham, NC 27710
Phone (919) 668-1000
Email address sulli025@mc.duke.edu

Research areas

  • Late effects of cancer treatment and stem cell transplantation 
  • Chronic graft-versus-host disease 
  • Transplantation for sickle cell and autoimmune diseases 
  • Knowledge engineering

Overview
Early on, Dr. Sullivan and the team at Fred Hutchinson Cancer Research Center developed a systematic investigative approach for the diagnosis and treatment of chronic graft-versus-host disease (GVHD), the major cause of late morbidity and non-relapse mortality following allogeneic stem cell transplantation (SCT). As a result of this work, it became clear that blood and marrow transplant recipients require systematic long-term follow-up to evaluate and treat late complications of high-dose chemoradiotherapy and SCT.

The program grew into a large multidisciplinary team, resulting in improvement in patient outcome and quality of life. Through the late events project, he also contributed to outcomes research, computer decision support systems, and knowledge engineering for follow-up care. With quality of life as a focus, research pursued the application of SCT to diseases with high morbidity but little immediate mortality. For young patients with advanced, symptomatic sickle cell disease, myeloablative conditioning and SCT from an HLA-identical sibling has led to an 86% long-term survival free of sickle cell disease. For individuals with autoimmune diseases such as multiple sclerosis, scleroderma, and systemic lupus erythematosus, current therapy is often incomplete and significant morbidity from the disease or its treatment is observed.

Recent preclinical and clinical data suggest that high-dose immunosupression and SCT can halt the progression and, in some settings, reverse the course of autoimmune diseases. Since his arrival at Duke University, over 30 centers nationwide are participating in Duke-led phase II and III trials to test the toxicity, efficacy, and quality of life following autologous and allogeneic stem cell transplantation for autoimmune diseases.

These trials will also serve as platforms to study the immune repertoire and mechanistic pathways before and after SCT to gain greater insight into the basic mechanisms of autoimmunity.

A national repository of tissue and cell specimens is also part of these NIH-supported trials to further promote scientific study from these unique patients.

In Their Words

Education and Training

  • M.D., Indiana University at Indianapolis, 1971

Publications

Radich, J. P., G. Gehly, T. Gooley, E. Bryant, R. A. Clift, S. Collins, S. Edmands, J. Kirk, A. Lee, and P. Kessler. “Polymerase chain reaction detection of the BCR-ABL fusion transcript after allogeneic marrow transplantation for chronic myeloid leukemia: results and implications in 346 patients..” Blood 85, no. 9 (May 1, 1995): 2632–38.

PMID
7727789
Scholars@Duke

Demirer, T., C. H. Weaver, C. D. Buckner, F. B. Petersen, W. I. Bensinger, J. Sanders, R. A. Clift, K. Lilleby, C. Anasetti, and P. Martin. “High-dose cyclophosphamide, carmustine, and etoposide followed by allogeneic bone marrow transplantation in patients with lymphoid malignancies who had received prior dose-limiting radiation therapy..” J Clin Oncol 13, no. 3 (March 1995): 596–602. https://doi.org/10.1200/JCO.1995.13.3.596.

PMID
7884421
Full Text

Walters, M. C., K. M. Sullivan, F. Bernaudin, G. Souillet, J. P. Vannier, F. L. Johnson, C. Lenarsky, D. Powars, N. Bunin, and K. Ohene-Frempong. “Neurologic complications after allogeneic marrow transplantation for sickle cell anemia..” Blood 85, no. 4 (February 15, 1995): 879–84.

PMID
7849310
Scholars@Duke

Bush, N. E., M. Haberman, G. Donaldson, and K. M. Sullivan. “Quality of life of 125 adults surviving 6-18 years after bone marrow transplantation..” Soc Sci Med 40, no. 4 (February 1995): 479–90. https://doi.org/10.1016/0277-9536(94)00153-k.

PMID
7725122
Full Text

Clift, R. A., C. D. Buckner, E. D. Thomas, E. Bryant, C. Anasetti, W. I. Bensinger, R. Bowden, H. J. Deeg, K. C. Doney, and L. D. Fisher. “Marrow transplantation for patients in accelerated phase of chronic myeloid leukemia..” Blood 84, no. 12 (December 15, 1994): 4368–73.

PMID
7527674
Scholars@Duke

Weaver, C. H., R. A. Clift, H. J. Deeg, R. Storb, F. R. Appelbaum, W. Bensinger, K. Doney, J. A. Hansen, P. O. Martin, and J. Sanders. “Effect of graft-versus-host disease prophylaxis on relapse in patients transplanted for acute myeloid leukemia..” Bone Marrow Transplant 14, no. 6 (December 1994): 885–93.

PMID
7711667
Scholars@Duke

Weaver, C. H., F. B. Petersen, F. R. Appelbaum, W. I. Bensinger, O. Press, P. Martin, B. Sandmaier, H. J. Deeg, J. A. Hansen, and M. Brunvand. “High-dose fractionated total-body irradiation, etoposide, and cyclophosphamide followed by autologous stem-cell support in patients with malignant lymphoma..” J Clin Oncol 12, no. 12 (December 1994): 2559–66. https://doi.org/10.1200/JCO.1994.12.12.2559.

PMID
7989929
Full Text

Robinson, N., and K. M. Sullivan. “Complications of allogeneic bone marrow transplantation..” Curr Opin Hematol 1, no. 6 (November 1994): 406–11.

PMID
9371314
Scholars@Duke

Clift, R. A., C. D. Buckner, E. D. Thomas, W. I. Bensinger, R. Bowden, E. Bryant, H. J. Deeg, K. C. Doney, L. D. Fisher, and J. A. Hansen. “Marrow transplantation for chronic myeloid leukemia: a randomized study comparing cyclophosphamide and total body irradiation with busulfan and cyclophosphamide..” Blood 84, no. 6 (September 15, 1994): 2036–43.

PMID
8081005
Scholars@Duke

Siadak, M., and K. M. Sullivan. “The management of chronic graft-versus-host disease..” Blood Rev 8, no. 3 (September 1994): 154–60.

PMID
7529605
Scholars@Duke

Pages